Copertina

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Saqr Alsakarneh, Razan Aburumman, Mohammad Bilal, Adam S. Faye, Jana G. Hashash, Aasma Shaukat
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study
di: Saqr Alsakarneh, et al.
Pubblicazione: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
di: Catherine Z. Tang, et al.
Pubblicazione: (2025)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
di: Aisha Alawi, et al.
Pubblicazione: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
di: Bo Li, et al.
Pubblicazione: (2024)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
di: Conrado Fernandez‐Rodriguez, et al.
Pubblicazione: (2024)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer
di: Alexandra Hickey, et al.
Pubblicazione: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
di: Purab Patel, et al.
Pubblicazione: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease
di: Jeli Mendoza, et al.
Pubblicazione: (2024)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
di: Monica E. W. Derks, et al.
Pubblicazione: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
di: Leyu Zhou, et al.
Pubblicazione: (2024)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
di: Matthew D. Coates, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
di: Marco Vincenzo Lenti, et al.
Pubblicazione: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
di: Agnes Hiu Yan Ho, et al.
Pubblicazione: (2025)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
di: Jörn M. Schattenberg, et al.
Pubblicazione: (2026)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
di: Selena Z. Kuo, et al.
Pubblicazione: (2025)

Autoimmune Hepatitis and Vitamin D Deficiency: A Nationwide Perspective
di: Yassine Kilani, et al.
Pubblicazione: (2024)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
di: Uma Mahadevan, et al.
Pubblicazione: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
di: Quinn Goddard, et al.
Pubblicazione: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
di: Brigida Barberio, et al.
Pubblicazione: (2026)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
di: Ao Gao, et al.
Pubblicazione: (2026)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
di: Huiying Lin, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
di: Stephanie Gold, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
di: Nicholas Clark, et al.
Pubblicazione: (2025)

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
di: Ellen Werner, et al.
Pubblicazione: (2026)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
di: Shamim Joudaki, et al.
Pubblicazione: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
di: Dhruv Ahuja, et al.
Pubblicazione: (2025)

Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
di: Mariko Maxwell, et al.
Pubblicazione: (2026)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
di: Nadir Abbas, et al.
Pubblicazione: (2025)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
di: Lynna Chen, et al.
Pubblicazione: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
di: Joyce Wing Yan Mak
Pubblicazione: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
di: Cristina Rubín de Célix, et al.
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
di: Cong Dai, et al.
Pubblicazione: (2024)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
di: Jane Lim, et al.
Pubblicazione: (2025)